<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25247297</article-id><article-id pub-id-type="pmc">4172686</article-id><article-id pub-id-type="publisher-id">PONE-D-14-18298</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0108562</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetics of Disease</subject><subject>Gene Types</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Haplotype Analyses of DNA Repair Gene Polymorphisms and Their Role in Ulcerative Colitis</article-title><alt-title alt-title-type="running-head"><italic>RAD51</italic>, <italic>XRCC3</italic> and <italic>hMSH2</italic> Polymorphism and Ulcerative Colitis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bardia</surname><given-names>Avinash</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tiwari</surname><given-names>Santosh K.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vishwakarma</surname><given-names>Sandeep K.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Habeeb</surname><given-names>Md. Aejaz</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nallari</surname><given-names>Pratibha</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sultana</surname><given-names>Shaik A.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pasha</surname><given-names>Shaik A.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Reddy</surname><given-names>Yugandhar P.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Aleem A.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences, Kanchanbagh, Hyderabad, Andhra Pradesh, India</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Genetics, Osmania University, Hyderabad, Andhra Pradesh, India</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>College of Applied Medical Sciences, King Saud University, Riyadh, Kingdom of Saudi Arabia</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Neurobiology lab, Department of Zoology, University College of Sciences, Osmania University, Hyderabad, Andhra Pradesh, India</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Castresana</surname><given-names>Javier S.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Navarra, Spain</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>aleem_a_khan@rediffmail.com</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: AB SKT SKV MAH PN SAS SAP YRP AAK. Performed the experiments: AB SKV MAH. Analyzed the data: AB SKT SKV MAH PN SAS SAP YRP AAK. Contributed reagents/materials/analysis tools: PN AAK. Contributed to the writing of the manuscript: AB SKT SKV MAH PN SAS SAP YRP AAK.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>9</month><year>2014</year></pub-date><volume>9</volume><issue>9</issue><elocation-id>e108562</elocation-id><history><date date-type="received"><day>25</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Bardia et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Bardia et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Ulcerative colitis (UC) is a major clinical form of inflammatory bowel disease. UC is characterized by mucosal inflammation limited to the colon, always involving the rectum and a variable extent of the more proximal colon in a continuous manner. Genetic variations in DNA repair genes may influence the extent of repair functions, DNA damage, and thus the manifestations of UC. This study thus evaluated the role of polymorphisms of the genes involved in DNA repair mechanisms. A total of 171 patients and 213 controls were included. Genotyping was carried out by ARMS PCR and PCR-RFLP analyses for <italic>RAD51</italic>, <italic>XRCC</italic>3 and <italic>hMSH2</italic> gene polymorphisms. Allelic and genotypic frequencies were computed in both control &#x00026; patient groups and data was analyzed using appropriate statistical tests. The frequency of &#x02018;A&#x02019; allele of <italic>hMSH</italic>2 in the UC group caused statistically significant increased risk for UC compared to controls (OR 1.64, 95% CI 1.16&#x02013;2.31, <italic>p</italic>&#x0200a;=&#x0200a;0.004). Similarly, the CT genotype of <italic>XRCC</italic>3 gene was predominant in the UC group and increased the risk for UC by 1.75 fold compared to controls (OR 1.75, 95% CI 1.15&#x02013;2.67, <italic>p</italic>&#x0200a;=&#x0200a;0.03), further confirming the risk of &#x02018;T&#x02019; allele in UC. The GC genotype frequency of <italic>RAD</italic>51 gene was significantly increased (<italic>p</italic>&#x0200a;=&#x0200a;0.02) in the UC group (50.3%) compared to controls (38%). The GC genotype significantly increased the risk for UC compared to GG genotype by 1.73 fold (OR 1.73, 95% CI 1.14&#x02013;2.62, <italic>p</italic>&#x0200a;=&#x0200a;0.02) confirming the strong association of &#x02018;C&#x02019; allele with UC. Among the controls, the SNP loci combination of <italic>hMSH</italic>2:<italic>XRCC</italic>3 were in perfect linkage. The GTC and ACC haplotypes were found to be predominant in UC than controls with a 2.28 and 2.93 fold significant increase risk of UC.</p></abstract><funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and the Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and the Supporting Information files.</p></notes></front><body><sec id="s1"><title>Introduction</title><p>The repair of damaged DNA forms an integral part of cell rejuvenation and is known to protect against different diseases <xref rid="pone.0108562-Friedberg1" ref-type="bibr">[1]</xref>. Approximately four major DNA repair pathways viz., nucleotide excision repair (NER), base excision repair (BER), double strand break repair (DBR) and mismatch repair (MMR) <xref rid="pone.0108562-Friedberg2" ref-type="bibr">[3]</xref>&#x02013;<xref rid="pone.0108562-Wood1" ref-type="bibr">[5]</xref> operate on specific types of damaged DNA <xref rid="pone.0108562-Goode1" ref-type="bibr">[2]</xref>. A deficiency in DNA repair capacity due to gene mutations can lead to genomic instability and disease susceptibility <xref rid="pone.0108562-Benhamou1" ref-type="bibr">[6]</xref>.</p><p>The mismatch repair human mutS homolog 2 (<italic>hMSH2</italic>) genes are integral components of the DNA mismatch repair pathway. The <italic>hMSH2</italic> gene is located on chromosome 2p21, an area initially identified as an important candidate region for genes involved in hereditary nonpolyposis colorectal cancer (HNPCC) <xref rid="pone.0108562-Leach1" ref-type="bibr">[9]</xref>. <italic>hMSH2</italic> can form a heterodimer with one of the two other mismatch repair proteins, <italic>hMSH6</italic> or <italic>hMSH3</italic>
<xref rid="pone.0108562-Mitchell1" ref-type="bibr">[10]</xref>. An amino acid substitution at codon 322 (<italic>Gly</italic>322<italic>Asp</italic>) of <italic>hMSH</italic>2 may affect the heterodimer formation with other proteins. Other investigators have demonstrated that genotypes in this gene have an increased risk for colorectal cancer <xref rid="pone.0108562-Leach1" ref-type="bibr">[9]</xref>. The <italic>XRCC3</italic> and <italic>RAD</italic>51 gene encodes protein involved in homologous recombinational repair (HRR) of double strand DNA <xref rid="pone.0108562-Cui1" ref-type="bibr">[11]</xref>. The <italic>XRCC</italic>3 gene has a sequence variation in exon 7 (C18067T), which result in an amino acid substitution at codon 241 (<italic>Thr</italic>241<italic>Met</italic>). This substitution may affect its interaction with other proteins involved in DNA damage and repair <xref rid="pone.0108562-Matullo1" ref-type="bibr">[12]</xref>. Several study demonstrated that <italic>XRCC</italic>3 polymorphisms are implicated in breast cancer <xref rid="pone.0108562-Kuschel1" ref-type="bibr">[13]</xref>, lung cancer <xref rid="pone.0108562-Jacobsen1" ref-type="bibr">[14]</xref>. Among several polymorphisms in <italic>RAD</italic>51 gene, a functional SNP at position 135 in 5&#x02032; UTR, changing a guanine to cytosine, was reported. Recently, two important meta-analyses <xref rid="pone.0108562-Gao1" ref-type="bibr">[15]</xref>&#x02013;<xref rid="pone.0108562-Sun1" ref-type="bibr">[16]</xref>, covering tens of other studies and thousands of subjects, were unanimous to state that the variant allele of <italic>RAD51</italic> G135C may contribute to increased breast cancer susceptibility, which is in accordance with biological function study, which showed a more aggressive and poor prognosis phenotype <xref rid="pone.0108562-Costa1" ref-type="bibr">[17]</xref>.</p><p>UC is complex disease with a strong genetic component <xref rid="pone.0108562-Abreu1" ref-type="bibr">[7]</xref>. It is presumed to be a multifactorial interplay between host genetics and environmental factors, leading to an aberrant inflammatory response <xref rid="pone.0108562-Furusho1" ref-type="bibr">[8]</xref>. The present study explored the impact of polymorphisms in important DNA repair genes (<italic>hMSH2</italic>, <italic>XRCC</italic>3, <italic>RAD</italic>51) in UC. The role of polymorphisms in these genes and their relation in UC needs to be elucidated to understand the pathogenesis of UC.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Patients and study design</title><p>A total of 171 patients (104 males and 67 females) with UC and 213 (131 males and 82 females) healthy volunteers were included. Healthy controls were selected without any prior history of GI presentations, autoimmune diseases and infections. There was no history of malignancy in the control group or in the UC patient group. The patients were selected from the symptomatic subjects who underwent colonoscopy at the Department of Gastroenterology, Deccan College of Medical Sciences, Hyderabad, India. To avoid selection bias, extensive care was taken not to include any patient with concomitant chronic inflammatory diseases such as arthritis, upper GI disorder etc. All the patients were asked to provide maximum information about their symptoms, disease, duration, and history of any disease that could affect the study outcome. The study protocol was approved by the Institutional Ethics Committee, Deccan College of Medical Sciences, Hyderabad, India. All study participants were asked to provide their written and signed consent to be part of this study protocol.</p></sec><sec id="s2b"><title>Genotyping</title><p>Five milliliter (5 mL) of peripheral venous blood was collected by venipuncture from all the subjects. DNA was isolated from 200 &#x000b5;L whole blood using a commercially available kit (Bioserve Biotechnology Pvt. Ltd., Hyderabad, India). Polymorphisms at <italic>Thr</italic>241<italic>Met</italic> in the <italic>XRCC</italic>3 gene were screened by polymerase chain reaction (PCR) with specific primers as described elsewhere <xref rid="pone.0108562-Winsey1" ref-type="bibr">[18]</xref>. Polymorphisms at Gly322Asp in the <italic>hMSH</italic>2 gene and G135C in the <italic>RAD</italic>51 gene were determined by PCR-restriction fragment length polymorphism as described previously <xref rid="pone.0108562-Poplawski1" ref-type="bibr">[19]</xref>. The 252 bp PCR product was digested at 37&#x000b0;C for 1 hour with 5 U of the restriction enzyme <italic>Hinf</italic>I. The <italic>Asp</italic> allele was identified by a 70 and 182 bp fragments and the <italic>Gln</italic> allele as 252 bp. For <italic>RAD</italic>51 gene the 157 bp PCR product was digested at 37&#x000b0;C for 1 hour with 5 U of the restriction enzyme <italic>MvaI</italic>. G allele was identified as 157 bp and C allele was identified by 86 and 71 bp fragments.</p></sec><sec id="s2c"><title>Statistical Analysis</title><p>The sample size was determined by using the openEPi statistics and 95% of confidence was used to detect the results with 90% of sample power. Odds ratios, with 95% confidence intervals were calculated to compare allele and genotype frequencies. The extent of linkage disequilibrium (LD) was expressed in terms of the maximum likelihood estimate of disequilibrium, D&#x02032;. For each of the SNPs, the covariates such as age and gender were adjusted. A Bonferroni test was performed for multiple testing because this method is valid for equal and unequal sample sizes and it can be used to correct any set of P values for multiple comparisons. Statistical analysis was carried out using SNPstats software, available online (<ext-link ext-link-type="uri" xlink:href="http://www.bioinfo.iconcologia.net/SNPstats">www.bioinfo.iconcologia.net/SNPstats</ext-link>) and Haploview software. For all tests, significance level was set as p&#x0003c;0.05.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Distribution of allelic and genotypic frequency of G322A polymorphisms in <italic>hMSH</italic>2 gene</title><p>The frequency of <bold>&#x02018;A&#x02019;</bold> allele was found to be predominant in UC group compared to controls (27% vs 18% respectively), with a 1.64 folds increased risk for UC (OR 1.64, 95% CI 1.16&#x02013;2.31, <italic>p</italic>&#x0200a;=&#x0200a;0.004) <bold>(<xref ref-type="table" rid="pone-0108562-t001">Table 1</xref>)</bold>. Heterozygotes (GA) were found to be predominant in the UC group compared to controls (49.1%, 35.7% respectively, <italic>p</italic>&#x0200a;=&#x0200a;0.004) with 1.81 folds increased risk for UC, which was statistically significant (OR 1.81, 95% CI 1.20&#x02013;2.74, <italic>p</italic>&#x0200a;=&#x0200a;0.004). Based on the dominant model, combination of GA+AA genotypes was also observed to be associated with high risk for UC (OR 1.87, 95% CI 1.24&#x02013;2.82, <italic>p</italic>&#x0200a;=&#x0200a;0.002). In recessive model no such variation was observed (compared with GG+GA) (OR 5.08, 95% CI 0.56&#x02013;45.81, <italic>p</italic>&#x0200a;=&#x0200a;0.1) <bold>(<xref ref-type="table" rid="pone-0108562-t001">Table 1</xref>)</bold>. Whereas in the overdominant model, GA (Compared with GG+AA genotype) genotype found to be associated with a 1.74 folds increased risk for UC (OR 1.74, 95% CI 1.15&#x02013;2.62, <italic>p</italic>&#x0200a;=&#x0200a;0.007), further confirming the risk of <bold>&#x02018;A&#x02019;</bold> allele in UC <bold>(<xref ref-type="table" rid="pone-0108562-t002">Table 2</xref>)</bold>.</p><table-wrap id="pone-0108562-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.t001</object-id><label>Table 1</label><caption><title>Allele frequency distributions of <italic>hMSH</italic>2 <italic>XRCC</italic>3 <italic>RAD</italic>51 (G135C) in UC and healthy controls.</title></caption><alternatives><graphic id="pone-0108562-t001-1" xlink:href="pone.0108562.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Controls (213)</td><td colspan="2" align="left" rowspan="1">Patients (171)</td><td colspan="2" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Allele</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Freq</td><td align="left" rowspan="1" colspan="1">N</td><td align="left" rowspan="1" colspan="1">Freq</td><td align="left" rowspan="1" colspan="1">OR 95% CI</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>- value</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">
<italic>hMSH</italic>2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>G</bold>
</td><td align="left" rowspan="1" colspan="1">348</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">250</td><td align="left" rowspan="1" colspan="1">0.73</td><td align="left" rowspan="1" colspan="1">0.60 (0.43&#x02013;0.85)</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>A</bold>
</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">
<bold>1.64 (1.16&#x02013;2.31)</bold>
</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td colspan="7" align="left" rowspan="1">
<italic>XRCC</italic>3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>C</bold>
</td><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">0.81</td><td align="left" rowspan="1" colspan="1">256</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.69 (0.49&#x02013;0.98)</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>T</bold>
</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">0.19</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">0.25</td><td align="left" rowspan="1" colspan="1">
<bold>1.43 (1.01&#x02013;2.01</bold>)</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td colspan="7" align="left" rowspan="1">
<italic>RAD</italic>51 (G135C)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>G</bold>
</td><td align="left" rowspan="1" colspan="1">335</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">242</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.65 (0.47&#x02013;0.91)</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>C</bold>
</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">
<bold>1.52 (1.09&#x02013;2.11)</bold>
</td><td align="left" rowspan="1" colspan="1">0.012</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone-0108562-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.t002</object-id><label>Table 2</label><caption><title>
<italic>hMSH</italic>2 genotypic distribution in UC compared to healthy controls.</title></caption><alternatives><graphic id="pone-0108562-t002-2" xlink:href="pone.0108562.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Patients</td><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Co-dominant</bold>
</td><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">136 (63.9%)</td><td align="left" rowspan="1" colspan="1">83 (48.5%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">76 (35.7%)</td><td align="left" rowspan="1" colspan="1">84 (49.1%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.81 (1.20&#x02013;2.74)</bold>
</td><td align="left" rowspan="1" colspan="1">0.0048</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">1 (0.5%)</td><td align="left" rowspan="1" colspan="1">4 (2.3%)</td><td align="left" rowspan="1" colspan="1">6.55 (0.72&#x02013;59.64)</td><td align="left" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Dominant</bold>
</td><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">136 (63.9%)</td><td align="left" rowspan="1" colspan="1">83 (48.5%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.0026</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G/A-A/A</td><td align="left" rowspan="1" colspan="1">77 (36.1%)</td><td align="left" rowspan="1" colspan="1">88 (51.5%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.87 (1.24&#x02013;2.82)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Recessive</bold>
</td><td align="left" rowspan="1" colspan="1">G/G-G/A</td><td align="left" rowspan="1" colspan="1">212 (99.5%)</td><td align="left" rowspan="1" colspan="1">167 (97.7%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A/A</td><td align="left" rowspan="1" colspan="1">1 (0.5%)</td><td align="left" rowspan="1" colspan="1">4 (2.3%)</td><td align="left" rowspan="1" colspan="1">5.08 (0.56&#x02013;45.81)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Over-dominant</bold>
</td><td align="left" rowspan="1" colspan="1">G/G-A/A</td><td align="left" rowspan="1" colspan="1">137 (64.3%)</td><td align="left" rowspan="1" colspan="1">87 (50.9%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.0079</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">76 (35.7%)</td><td align="left" rowspan="1" colspan="1">84 (49.1%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.74 (1.15&#x02013;2.62)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec><sec id="s3b"><title>Distribution of allelic and genotypic frequency of C241T polymorphisms in <italic>XRCC</italic>3 gene</title><p>The frequency of <bold>&#x02018;T&#x02019;</bold> allele was found to be predominant in UC group compared to controls (25% vs 19% respectively), with a 1.43 folds increased risk for UC (OR 1.43, 95% CI 1.01&#x02013;2.01, <italic>p</italic>&#x0200a;=&#x0200a;0.041) <bold>(<xref ref-type="table" rid="pone-0108562-t003">Table 3</xref>)</bold>.</p><table-wrap id="pone-0108562-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.t003</object-id><label>Table 3</label><caption><title>
<italic>XRCC</italic>3 genotypic distribution in patients with UC and healthy controls.</title></caption><alternatives><graphic id="pone-0108562-t003-3" xlink:href="pone.0108562.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Patients</td><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Co-dominant</bold>
</td><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">138 (64.8%)</td><td align="left" rowspan="1" colspan="1">89 (52%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">69 (32.4%)</td><td align="left" rowspan="1" colspan="1">78 (45.6%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.75 (1.15&#x02013;2.67)</bold>
</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">6 (2.8%)</td><td align="left" rowspan="1" colspan="1">4 (2.3%)</td><td align="left" rowspan="1" colspan="1">1.03 (0.28&#x02013;3.77)</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Dominant</bold>
</td><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">138 (64.8%)</td><td align="left" rowspan="1" colspan="1">89 (52%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C/T-T/T</td><td align="left" rowspan="1" colspan="1">75 (35.2%)</td><td align="left" rowspan="1" colspan="1">82 (48%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.70 (1.12&#x02013;2.56)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Recessive</bold>
</td><td align="left" rowspan="1" colspan="1">C/C-C/T</td><td align="left" rowspan="1" colspan="1">207 (97.2%)</td><td align="left" rowspan="1" colspan="1">167 (97.7%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">T/T</td><td align="left" rowspan="1" colspan="1">6 (2.8%)</td><td align="left" rowspan="1" colspan="1">4 (2.3%)</td><td align="left" rowspan="1" colspan="1">0.83 (0.23&#x02013;2.98)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Over-dominant</bold>
</td><td align="left" rowspan="1" colspan="1">C/C-T/T</td><td align="left" rowspan="1" colspan="1">144 (67.6%)</td><td align="left" rowspan="1" colspan="1">93 (54.4%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.0081</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">69 (32.4%)</td><td align="left" rowspan="1" colspan="1">78 (45.6%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.75 (1.15&#x02013;2.65)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>CT genotype were found to be predominant in the UC group compared to controls (45.6%, 32.4% respectively, <italic>p</italic>&#x0200a;=&#x0200a;0.03) with 1.75 folds increased risk for UC, which was statistically significant (OR 1.75, 95% CI 1.15&#x02013;2.67, <italic>p</italic>&#x0200a;=&#x0200a;0.03) <bold>(<xref ref-type="table" rid="pone-0108562-t003">Table 3</xref>)</bold>. Based on the dominant model, combination of CT+TT genotypes were also observed are at high risk for UC (OR 1.70, 95% CI 1.12&#x02013;2.56, <italic>p</italic>&#x0200a;=&#x0200a;0.012) <bold>(<xref ref-type="table" rid="pone-0108562-t003">Table 3</xref>)</bold>. Whereas in the recessive model, TT genotype (compared with CC+CT genotype) was insignificant in UC compare to control (OR 0.83, 95% CI 0.23&#x02013;2.98, <italic>p</italic>&#x0200a;=&#x0200a;0.77) but the overdominant model, CT genotype (compared with CC+TT genotype) is a risk genotype for UC (OR 1.75, 95% CI 1.15&#x02013;2.65, <italic>p</italic>&#x0200a;=&#x0200a;0.0082), further confirming the risk of <bold>&#x02018;T&#x02019;</bold> allele in UC <bold>(<xref ref-type="table" rid="pone-0108562-t003">Table 3</xref>)</bold>.</p></sec><sec id="s3c"><title>Distribution of allelic and genotypic frequency of G135C polymorphisms in <italic>RAD</italic>51 gene</title><p>The <italic>RAD</italic>51 gene encodes protein involved in homologous recombinational repair (HRR) of double strand DNA (Cui <italic>et al.</italic>, 1999). The <italic>RAD51</italic> protein is responsible for the central activity of the HRR pathway, in which it catalyses the invasion of the broken ends of the DSB into the intact sister chromatid.</p><p>The <bold>&#x02018;C&#x02019;</bold> allele frequency was found to be predominant in UC group (29%) compared to the control group (21%) <bold>(<xref ref-type="table" rid="pone-0108562-t004">Table 4</xref>)</bold>.</p><table-wrap id="pone-0108562-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.t004</object-id><label>Table 4</label><caption><title>
<italic>RAD</italic>51 genotypic distribution in patients with UC compared to healthy controls.</title></caption><alternatives><graphic id="pone-0108562-t004-4" xlink:href="pone.0108562.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Model</td><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">Controls</td><td align="left" rowspan="1" colspan="1">Patients</td><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td align="left" rowspan="1" colspan="1">
<italic>p</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Co-dominant</bold>
</td><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">127 (59.6%)</td><td align="left" rowspan="1" colspan="1">78 (45.6%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G/C</td><td align="left" rowspan="1" colspan="1">81 (38%)</td><td align="left" rowspan="1" colspan="1">86 (50.3%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.73 (1.14&#x02013;2.62)</bold>
</td><td align="left" rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">5 (2.4%)</td><td align="left" rowspan="1" colspan="1">7 (4.1%)</td><td align="left" rowspan="1" colspan="1">2.28 (0.70&#x02013;7.43)</td><td align="left" rowspan="1" colspan="1">0.171</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Dominant</bold>
</td><td align="left" rowspan="1" colspan="1">G/G</td><td align="left" rowspan="1" colspan="1">127 (59.6%)</td><td align="left" rowspan="1" colspan="1">78 (45.6%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.0062</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G/C-C/C</td><td align="left" rowspan="1" colspan="1">86 (40.4%)</td><td align="left" rowspan="1" colspan="1">93 (54.4%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.76 (1.17&#x02013;2.64)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Recessive</bold>
</td><td align="left" rowspan="1" colspan="1">G/G-G/C</td><td align="left" rowspan="1" colspan="1">208 (97.7%)</td><td align="left" rowspan="1" colspan="1">164 (95.9%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C/C</td><td align="left" rowspan="1" colspan="1">5 (2.4%)</td><td align="left" rowspan="1" colspan="1">7 (4.1%)</td><td align="left" rowspan="1" colspan="1">1.78 (0.55&#x02013;5.70)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Over-dominant</bold>
</td><td align="left" rowspan="1" colspan="1">G/G-C/C</td><td align="left" rowspan="1" colspan="1">132 (62%)</td><td align="left" rowspan="1" colspan="1">85 (49.7%)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">G/C</td><td align="left" rowspan="1" colspan="1">81 (38%)</td><td align="left" rowspan="1" colspan="1">86 (50.3%)</td><td align="left" rowspan="1" colspan="1">
<bold>1.65 (1.10&#x02013;2.48)</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>GC genotypic frequency was found to be predominant in UC group (50.3%) compared to controls (38%) with the difference being statistically significant (<italic>p</italic>&#x0200a;=&#x0200a;0.02). The GC genotype was found to be associated with 1.73 folds increased risk for UC compared to GG genotype (OR 1.73, 95% CI 1.14&#x02013;2.62, <italic>p</italic>&#x0200a;=&#x0200a;0.02) <bold>(<xref ref-type="table" rid="pone-0108562-t004">Table 4</xref>)</bold>. Based on the dominant model, combination of GC+CC genotypes were also observed to be associated with high risk for UC (OR 1.76, 95% CI 1.17&#x02013;2.64, <italic>p</italic>&#x0200a;=&#x0200a;0.006). Based on the recessive model CC genotype did not show any statistical significant compare with the combination of GG+GC genotype (OR 1.78, 95% CI 0.55&#x02013;5.70, <italic>p</italic>&#x0200a;=&#x0200a;0.33) <bold>(<xref ref-type="table" rid="pone-0108562-t004">Table 4</xref>)</bold>. Whereas overdominant model GC (Compared with GG+CC genotype) genotype were also observed to be associated with high risk for UC (OR 1.65, 95% CI 1.10&#x02013;2.48, p&#x0200a;=&#x0200a;0.016), further strengthening the association of <bold>&#x02018;C&#x02019;</bold> allele with UC manifestation <bold>(<xref ref-type="table" rid="pone-0108562-t004">Table 4</xref>)</bold>.</p></sec><sec id="s3d"><title>Linkage Disequilibrium</title><p>In present study, pairwise LD estimates were obtained for the case and control group separately for the <italic>hMSH</italic>2, <italic>XRCC</italic>3 and <italic>RAD</italic>51 gene polymorphisms. The analysis revealed that most of the SNP marker combinations exhibited low LD scores, with the exception of few combinations that showed differential pattern of high LD scores in each of the analysis groups (cases and controls).</p><p>While in the control group, the SNP loci combination of <italic>hMSH</italic>2: <italic>XRCC</italic>3 were in perfect LD. In contrast to this, the cases did not show any SNP loci combination with a perfect LD score <bold>(<xref ref-type="fig" rid="pone-0108562-g001">Figure 1</xref>)</bold>. Pairwise LD score were also calculated for the three polymorphisms studied <bold>(<xref ref-type="table" rid="pone-0108562-t005">Table 5</xref>)</bold>.</p><fig id="pone-0108562-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.g001</object-id><label>Figure 1</label><caption><title>Linkage disequilibrium observed in control and ulcerative colitis groups.</title></caption><graphic xlink:href="pone.0108562.g001"/></fig><table-wrap id="pone-0108562-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.t005</object-id><label>Table 5</label><caption><title>Pairwise Linkage Disequilibrium estimates in controls and Ulcerative colitis group.</title></caption><alternatives><graphic id="pone-0108562-t005-5" xlink:href="pone.0108562.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">D&#x02032;</td><td align="left" rowspan="1" colspan="1">LOD</td><td align="left" rowspan="1" colspan="1">r<sup>2</sup>
</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1">
<bold>Controls</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>RAD</italic>51: <italic>hMSH</italic>2</td><td align="left" rowspan="1" colspan="1">0.027</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>RAD</italic>51:<italic>XRCC3</italic>
</td><td align="left" rowspan="1" colspan="1">0.065</td><td align="left" rowspan="1" colspan="1">0.14</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>hMSH</italic>2: <italic>XRCC3</italic>
</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.67</td><td align="left" rowspan="1" colspan="1">0.053</td></tr><tr><td colspan="4" align="left" rowspan="1">
<bold>Ulcerative colitis</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>RAD</italic>51: <italic>hMSH</italic>2</td><td align="left" rowspan="1" colspan="1">
<bold>0.11</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>RAD</italic>51:<italic>XRCC3</italic>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.068</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.09</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>hMSH</italic>2: <italic>XRCC3</italic>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.021</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0</bold>
</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="s3e"><title>Haplotype Analysis</title><p>Haplotype analysis is believed to be more informative approach in strengthening the genetic influence on disease manifestation than testing for individual genotypes, hence haplotypes were constructed based on the four polymorphisms and analyzed for the possible association with UC.</p><p>Of the all haplotypes obtained <bold>(<xref ref-type="table" rid="pone-0108562-t006">Table 6</xref>)</bold>, one haplotypes carrying the recessive allele of <italic>XRCC</italic>3 and <italic>RAD</italic>51 polymorphism, G<bold>TC</bold> were found to be significantly predominant in the disease group. The G<bold>TC</bold> haplotype was found to be predominant in UC than controls with a <bold>2.28</bold> fold significant increase, (OR 2.28, 95% CI 1.08&#x02013;4.83, <italic>p</italic>&#x0200a;=&#x0200a;0.032). Another haplotypes carries the recessive allele of <italic>hMSH</italic>2 and <italic>RAD</italic>51 gene, <bold>A</bold>C<bold>C</bold> haplotype were found to be significant in UC when compared with control (OR 2.93, 95% CI 1.18&#x02013;7.28, p&#x0200a;=&#x0200a;0.021). Whereas the other haplotype did not shown any statistically significant. Hence these two haplotypes could be the risk haplotype for UC.</p><table-wrap id="pone-0108562-t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0108562.t006</object-id><label>Table 6</label><caption><title>Haplotype association with response.</title></caption><alternatives><graphic id="pone-0108562-t006-6" xlink:href="pone.0108562.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="9" align="left" rowspan="1">Haplotype association with response (n&#x0200a;=&#x0200a;384, crude analysis)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>hMSH</italic>2</td><td align="left" rowspan="1" colspan="1">
<italic>XRCC</italic>3</td><td align="left" rowspan="1" colspan="1">
<italic>RAD</italic>51</td><td align="left" rowspan="1" colspan="1">Freq</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">Patient</td><td align="left" rowspan="1" colspan="1">OR (95% CI)</td><td align="left" rowspan="1" colspan="1">P-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.4695</td><td align="left" rowspan="1" colspan="1">0.5006</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.1335</td><td align="left" rowspan="1" colspan="1">0.1462</td><td align="left" rowspan="1" colspan="1">0.1182</td><td align="left" rowspan="1" colspan="1">1.10 (0.56&#x02013;2.18)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">0.1246</td><td align="left" rowspan="1" colspan="1">0.1267</td><td align="left" rowspan="1" colspan="1">0.1242</td><td align="left" rowspan="1" colspan="1">1.42 (0.73&#x02013;2.77)</td><td align="left" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">T</td><td align="left" rowspan="1" colspan="1">G</td><td align="left" rowspan="1" colspan="1">0.1163</td><td align="left" rowspan="1" colspan="1">0.1396</td><td align="left" rowspan="1" colspan="1">0.0847</td><td align="left" rowspan="1" colspan="1">0.88 (0.45&#x02013;1.72)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">
<bold>G</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>T</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>C</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0683</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0921</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.28 (1.08&#x02013;4.83)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.032</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">
<bold>A</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>C</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>C</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.055</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0364</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0761</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.93 (1.18&#x02013;7.28)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.021</bold>
</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>UC is a chronic inflammatory bowel disease (IBD) of unknown aetiology. The pathophysiology of UC relates to a dysregulated mucosal immune response to antigenic stimulation from gut microbiota on a background of genetic susceptibility <xref rid="pone.0108562-Danese1" ref-type="bibr">[20]</xref>.</p><p>Our findings elucidate that the GA genotypic frequency of <italic>hMSH</italic>2 was relatively higher in patients than in control (OR 1.81, 95% CI 1.20&#x02013;2.74, <italic>p</italic>&#x0200a;=&#x0200a;0.004) which is in absolute conformity with data of Poplawski <italic>et al.</italic>, (2006) <xref rid="pone.0108562-Pachkowski1" ref-type="bibr">[21]</xref> Significant association of <italic>Gly</italic>322<italic>Asp</italic> polymorphism of the <italic>hMSH2</italic> gene with breast cancer and colorectal cancer <xref rid="pone.0108562-Chio1" ref-type="bibr">[22]</xref> was reported. The frequency of A allele was found to be predominant in UC group compared to controls, with a 1.64 folds increased risk for UC (OR 1.64, 95% CI 1.16&#x02013;2.31, <italic>p</italic>&#x0200a;=&#x0200a;0.004).</p><p>Our study on genotype CT of <italic>XRCC3</italic> gene polymorphisms showed statistical significance with an OR of 1.75 and 95% CI of 1.15&#x02013;2.67, <italic>p</italic>&#x0200a;=&#x0200a;0.03. Interestingly, similar result was observed in melanoma and bladder cancer <xref rid="pone.0108562-Winsey1" ref-type="bibr">[18]</xref>, <xref rid="pone.0108562-Matullo1" ref-type="bibr">[12]</xref>. Improta <italic>et al.</italic>, (2008) <xref rid="pone.0108562-Improta1" ref-type="bibr">[23]</xref> demonstrated a significant association between the <italic>XRCC</italic>3 Thr241Met polymorphism and colorectal and lung cancer. This <italic>XRCC</italic>3 codon 241 polymorphism was shown to have a significant association with colorectal <xref rid="pone.0108562-Mort1" ref-type="bibr">[24]</xref> and lung <xref rid="pone.0108562-Jacobsen1" ref-type="bibr">[14]</xref> cancer risk; hence, our findings are in agreement with those reported by Mort <italic>et al.</italic>, (2003) <xref rid="pone.0108562-Mort1" ref-type="bibr">[24]</xref>. But no association was found between this polymorphism and squamous cell carcinoma of the head and neck <xref rid="pone.0108562-Benhamou1" ref-type="bibr">[6]</xref>, gastric cancer <xref rid="pone.0108562-Shen1" ref-type="bibr">[25]</xref> or basal cell carcinoma <xref rid="pone.0108562-Jacobsen2" ref-type="bibr">[26]</xref>. The heterozyte (CT) and homozygote variant (TT) genotypes were associated with a decreased risk of bladder cancer but these results were not significant <xref rid="pone.0108562-Fontana1" ref-type="bibr">[27]</xref>. The study of Shen <italic>et al.</italic> (2003) <xref rid="pone.0108562-Shen2" ref-type="bibr">[28]</xref> was the first and the only one to suggest a protective role of <italic>XRCC</italic>3 codon 241 polymorphism against bladder cancer risk. The frequency of T allele was found to be high in UC group when compared to controls with a 1.43 folds increased risk for UC (OR 1.43, 95% CI 1.01&#x02013;2.01, <italic>p</italic>&#x0200a;=&#x0200a;0.041).</p><p>In <italic>RAD</italic>51, GC genotypic frequency was found to be predominant in UC group (50.3%) compared to controls (38%) with the difference being statistically significant (<italic>p</italic>&#x0200a;=&#x0200a;0.02). We found that the SNP in the <italic>RAD</italic>51 gene GC genotype (OR 1.73, 95% CI 1.14&#x02013;2.62, <italic>p</italic>&#x0200a;=&#x0200a;0.02) may be an important predictive determinant for UC. Hosseini <italic>et al.</italic>, (2013) <xref rid="pone.0108562-Hosseini1" ref-type="bibr">[29]</xref> also demonstrated that there was a significant association of breast cancer risk with <italic>RAD</italic>51 polymorphism. Wang <italic>et al.</italic>, (2001) <xref rid="pone.0108562-Wang1" ref-type="bibr">[30]</xref> identified a <italic>RAD</italic>51 SNP that may be associated with an increased risk of breast cancer and a lower risk of ovarian cancer. Krupa <italic>et al.</italic>, (2011) <xref rid="pone.0108562-Krupa1" ref-type="bibr">[31]</xref> found that CC genotype decreased the risk of colorectal cancer in the Polish population. Other data has shown that GC heterozygote of the <italic>RAD</italic>51 polymorphism may be associated with the increased risk of colorectal cancer development <xref rid="pone.0108562-Jarosiska1" ref-type="bibr">[32]</xref>. Makowska <italic>et al.</italic>, (2012) <xref rid="pone.0108562-Makowska1" ref-type="bibr">[33]</xref> demonstrated that the variant genotypes of the CC RAD51 polymorphism may be positively associated with colorectal carcinoma in the Polish population. The homozygote variant (CC) genotypes was not associated in UC cohort (OR 2.28, 95% CI 0.70&#x02013;7.43, <italic>p</italic>&#x0200a;=&#x0200a;0.17). However C allele frequency was found to be high in UC group (29%) when compared to the control group (21%). GC genotypic frequency was found to be predominant in UC group (50.3%) when compared to controls (38%) with the difference being statistically significant (<italic>p</italic>&#x0200a;=&#x0200a;0.02).</p><p>In the control group, the SNP loci combination of <italic>XRCC</italic>3:<italic>hMSH</italic>2 were in perfect LD, there was one other combination that demonstrated a moderate LD effect, i.e XRCC3: RAD51 (D&#x02032;&#x0200a;=&#x0200a;60). In contrast to this, the cases did not show any SNP loci combination with a perfect LD score. In a recent report, it was found that the 399Gln allele of <italic>XRCC</italic>1 was in complete linkage disequilibrium (LD) with the 280His allele of same gene (D&#x02032;&#x0200a;=&#x0200a;1.0) and the 280His allele was in complete LD with the 194Arg allele in <italic>XRCC</italic>1 gene (D&#x02032;&#x0200a;=&#x0200a;1.0) in both whites and African Americans <xref rid="pone.0108562-Pachkowski1" ref-type="bibr">[21]</xref> in cutaneous melanoma. G<bold>TC and ACC</bold> haplotypes could be the risk haplotypes for UC. T&#x02032; and &#x02018;C&#x02019; alleles of <italic>XRCC</italic>3 and <italic>RAD</italic>51 respectively contribution being significant in risk stratification of UC. Sant et al., (2011) <xref rid="pone.0108562-Sant1" ref-type="bibr">[34]</xref> identified that the CTC haplotype in BRCA1 gene was significantly associated with decreased mean number of breaks per cell (MBPC).</p><p>Further studies on the epistatic interactions are warranted to elucidate their possible underlying mechanisms. Since different populations have distinct genetic backgrounds, it is necessary to validate or replicate such associations with independent samples collected from other ethnic groups/populations.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0108562.s001"><label>Table S1</label><caption><p>
<bold>Haplotype data.</bold>
</p><p>(XLSX)</p></caption><media xlink:href="pone.0108562.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank the staff and administration of Centre for Liver Research and Diagnostics, Deccan College of Medical Sciences, Hyderabad, India and the Department of Genetics, Osmania University, Hyderabad, India for their support and cooperation through-out the study. Thanks are due to the patients and volunteers who participated in this study.</p></ack><ref-list><title>References</title><ref id="pone.0108562-Friedberg1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Friedberg</surname><given-names>EC</given-names></name> (<year>2003</year>) <article-title>DNA damage and repair</article-title>. <source>Nature</source>
<volume>421</volume>: <fpage>436</fpage>&#x02013;<lpage>440</lpage>.<pub-id pub-id-type="pmid">12540918</pub-id></mixed-citation></ref><ref id="pone.0108562-Goode1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Goode</surname><given-names>EL</given-names></name>, <name><surname>Ulrich</surname><given-names>CM</given-names></name>, <name><surname>Potter</surname><given-names>JD</given-names></name> (<year>2002</year>) <article-title>Polymorphisms in DNA repairs genes and associations with cancer risk</article-title>. <source>Cancer Epidemiol Biomarker Preven</source>
<volume>11</volume>: <fpage>1513</fpage>&#x02013;<lpage>1530</lpage>.</mixed-citation></ref><ref id="pone.0108562-Friedberg2"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Friedberg</surname><given-names>EC</given-names></name> (<year>2001</year>) <article-title>How nucleotide excision repair protects against cancer</article-title>. <source>Nature Reviews Cancer</source>
<volume>1</volume>: <fpage>22</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">11900249</pub-id></mixed-citation></ref><ref id="pone.0108562-Tauchi1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Tauchi</surname><given-names>H</given-names></name>, <name><surname>Kobayashi</surname><given-names>J</given-names></name>, <name><surname>Morishima</surname><given-names>K</given-names></name> (<year>2002</year>) <article-title>Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells</article-title>. <source>Nature</source>
<volume>420</volume>: <fpage>93</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">12422221</pub-id></mixed-citation></ref><ref id="pone.0108562-Wood1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Wood</surname><given-names>RD</given-names></name>, <name><surname>Mitchell</surname><given-names>M</given-names></name>, <name><surname>Sgouros</surname><given-names>J</given-names></name>, <name><surname>Lindahl</surname><given-names>T</given-names></name> (<year>2001</year>) <article-title>Human DNA repair genes</article-title>. <source>Science</source>
<volume>291</volume>: <fpage>1284</fpage>&#x02013;<lpage>1289</lpage>.<pub-id pub-id-type="pmid">11181991</pub-id></mixed-citation></ref><ref id="pone.0108562-Benhamou1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Benhamou</surname><given-names>S</given-names></name>, <name><surname>Sarasin</surname><given-names>A</given-names></name> (<year>2000</year>) <article-title>Variability in nucleotide excision repair and cancer risk: a review</article-title>. <source>Mutation Res</source>
<volume>462</volume>: <fpage>149</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">10767626</pub-id></mixed-citation></ref><ref id="pone.0108562-Abreu1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Abreu</surname><given-names>MT</given-names></name>, <name><surname>Sparrow</surname><given-names>MP</given-names></name> (<year>2006</year>) <article-title>Translational research in inflammatory bowel disease</article-title>. <source>The Mount Sinai Journal of Medicine</source>
<volume>73</volume>: <fpage>1067</fpage>&#x02013;<lpage>1073</lpage>.<pub-id pub-id-type="pmid">17285196</pub-id></mixed-citation></ref><ref id="pone.0108562-Furusho1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Furusho</surname><given-names>JKY</given-names></name>, <name><surname>Podolsky</surname><given-names>DK</given-names></name> (<year>2007</year>) <article-title>Innate immunity in inflammatory bowel disease</article-title>. <source>W J Gastroenterol</source>
<volume>13</volume>: <fpage>5577</fpage>&#x02013;<lpage>5580</lpage>.</mixed-citation></ref><ref id="pone.0108562-Leach1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Leach</surname><given-names>FS</given-names></name>, <name><surname>Nicolaides</surname><given-names>NC</given-names></name>, <name><surname>Papadopoulos</surname><given-names>N</given-names></name> (<year>1993</year>) <article-title>Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer</article-title>. <source>Cell</source>
<volume>75</volume>: <fpage>1215</fpage>&#x02013;<lpage>1225</lpage>.<pub-id pub-id-type="pmid">8261515</pub-id></mixed-citation></ref><ref id="pone.0108562-Mitchell1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Mitchell</surname><given-names>RJ</given-names></name>, <name><surname>Farrington</surname><given-names>SM</given-names></name>, <name><surname>Dunlop</surname><given-names>MG</given-names></name>, <name><surname>Campbell</surname><given-names>H</given-names></name> (<year>2002</year>) <article-title>Mismatch repair genes <italic>hMLH1</italic> and <italic>hMSH2</italic> and colorectal cancer: A HuGE Review</article-title>. <source>Ameri J Epidemiol</source>
<volume>56</volume>: <fpage>885</fpage>&#x02013;<lpage>902</lpage>.</mixed-citation></ref><ref id="pone.0108562-Cui1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Cui</surname><given-names>X</given-names></name>, <name><surname>Brenneman</surname><given-names>M</given-names></name>, <name><surname>Meyne</surname><given-names>J</given-names></name>, <name><surname>Oshimura</surname><given-names>M</given-names></name>, <name><surname>Goodwin</surname><given-names>EH</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells</article-title>. <source>Mutation Rese</source>
<volume>434</volume>: <fpage>75</fpage>&#x02013;<lpage>88</lpage>.</mixed-citation></ref><ref id="pone.0108562-Matullo1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Matullo</surname><given-names>GG</given-names></name>, <name><surname>Carturan</surname><given-names>S</given-names></name> (<year>2001</year>) <article-title>DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study</article-title>. <source>Internat J Cancer</source>
<volume>92</volume>: <fpage>562</fpage>&#x02013;<lpage>567</lpage>.</mixed-citation></ref><ref id="pone.0108562-Kuschel1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Kuschel</surname><given-names>B</given-names></name>, <name><surname>Auranen</surname><given-names>A</given-names></name>, <name><surname>McBride</surname><given-names>S</given-names></name>, <name><surname>Novik</surname><given-names>KL</given-names></name>, <name><surname>Antoniou</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Variants in DNA double-strand break repair genes and breast cancer susceptibility</article-title>. <source>Human Molecular Genetics</source>
<volume>11</volume>: <fpage>1399</fpage>&#x02013;<lpage>1407</lpage>.<pub-id pub-id-type="pmid">12023982</pub-id></mixed-citation></ref><ref id="pone.0108562-Jacobsen1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Jacobsen</surname><given-names>NR</given-names></name>, <name><surname>Raaschou-Nielsen</surname><given-names>O</given-names></name>, <name><surname>Nexo</surname><given-names>B</given-names></name>, <name><surname>Wallin</surname><given-names>H</given-names></name>, <name><surname>Overvad</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>XRCC3 polymorphisms and risk of lung cancer</article-title>. <source>Cancer Let</source>
<volume>213</volume>: <fpage>67</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">15312685</pub-id></mixed-citation></ref><ref id="pone.0108562-Gao1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Gao</surname><given-names>LB</given-names></name>, <name><surname>Pan</surname><given-names>XM</given-names></name>, <name><surname>Li</surname><given-names>LJ</given-names></name> (<year>2011</year>) <article-title>RAD51 135G/C polymorphism and breast cancer risk: a metaanalysis from 21 studies</article-title>. <source>Breast Cancer Res Treat</source>
<volume>125</volume>: <fpage>827</fpage>&#x02013;<lpage>835</lpage>.<pub-id pub-id-type="pmid">20640595</pub-id></mixed-citation></ref><ref id="pone.0108562-Sun1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Sun</surname><given-names>H</given-names></name>, <name><surname>Bai</surname><given-names>J</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name> (<year>2011</year>) <article-title>RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects</article-title>. <source>Breast Cancer Res Treat</source>
<volume>125</volume>: <fpage>157</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">20454923</pub-id></mixed-citation></ref><ref id="pone.0108562-Costa1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Costa</surname><given-names>S</given-names></name>, <name><surname>Pinto</surname><given-names>D</given-names></name>, <name><surname>Pereira</surname><given-names>D</given-names></name> (<year>2008</year>) <article-title>XRCC1 Arg399Gln and RAD51 5&#x02032;UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source>
<volume>109</volume>: <fpage>183</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">17616806</pub-id></mixed-citation></ref><ref id="pone.0108562-Winsey1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Winsey</surname><given-names>SL</given-names></name>, <name><surname>Haldar</surname><given-names>NA</given-names></name>, <name><surname>Marsh</surname><given-names>HP</given-names></name>, <name><surname>Bunce</surname><given-names>M</given-names></name>, <name><surname>Marshall</surname><given-names>SE</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>A variant within the DNA repair gene <italic>XRCC3</italic> is associated with the development of melanoma skin cancer</article-title>. <source>Cancer Research</source>
<volume>60</volume>: <fpage>5612</fpage>&#x02013;<lpage>5616</lpage>.<pub-id pub-id-type="pmid">11059748</pub-id></mixed-citation></ref><ref id="pone.0108562-Poplawski1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Poplawski</surname><given-names>T</given-names></name>, <name><surname>Zadrozny</surname><given-names>M</given-names></name>, <name><surname>Kolacinska</surname><given-names>A</given-names></name>, <name><surname>Rykala</surname><given-names>J</given-names></name>, <name><surname>Morawiec</surname><given-names>Z</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression</article-title>. <source>Bre Can Res Treat</source>
<volume>94</volume>: <fpage>199</fpage>&#x02013;<lpage>204</lpage>.</mixed-citation></ref><ref id="pone.0108562-Danese1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Danese</surname><given-names>S</given-names></name>, <name><surname>Fiocchi</surname><given-names>C</given-names></name> (<year>2006</year>) <article-title>Etiopathogenesis of inflammatory bowel diseases</article-title>. <source>W J Gastroenterol</source>
<volume>12</volume>: <fpage>4807</fpage>&#x02013;<lpage>4812</lpage>.</mixed-citation></ref><ref id="pone.0108562-Pachkowski1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Pachkowski</surname><given-names>BF</given-names></name>, <name><surname>Winkel</surname><given-names>S</given-names></name>, <name><surname>Kubota</surname><given-names>Y</given-names></name> (<year>2006</year>) <article-title>XRCC1 genotype and breast cancer: functional studies and epidemiologic data show interactions between XRCC1 codon 280 His and smoking</article-title>. <source>Cancer Res</source>
<volume>66</volume>: <fpage>2860</fpage>&#x02013;<lpage>2868</lpage>.<pub-id pub-id-type="pmid">16510609</pub-id></mixed-citation></ref><ref id="pone.0108562-Chio1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Chio</surname><given-names>YH</given-names></name>, <name><surname>Cotterchio</surname><given-names>M</given-names></name>, <name><surname>Eyssen</surname><given-names>GM</given-names></name>, <name><surname>Neerav</surname></name> (<year>2009</year>) <article-title>Penetrance of colorectal cancer among <italic>MLH1</italic>/<italic>MSH2</italic> carriers participating in the colorectal cancer familial registry in Ontario</article-title>. <source>Hereditary Cancer Clin Prac</source>
<volume>7</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="pone.0108562-Improta1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Improta</surname><given-names>G</given-names></name>, <name><surname>Sgambato</surname><given-names>A</given-names></name>, <name><surname>Bianchino</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Polymorphisms of the DNA repair genes <italic>XRCC1</italic> and <italic>XRCC3</italic> and risk of lung and colorectal cancer: a case-control study in a southern italian population</article-title>. <source>Anticancer Res</source>
<volume>28</volume>: <fpage>2941</fpage>&#x02013;<lpage>2946</lpage>.<pub-id pub-id-type="pmid">19031937</pub-id></mixed-citation></ref><ref id="pone.0108562-Mort1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Mort</surname><given-names>R</given-names></name>, <name><surname>Mo</surname><given-names>L</given-names></name>, <name><surname>McEwan</surname><given-names>C</given-names></name> (<year>2003</year>) <article-title>Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer</article-title>. <source>Br J Cancer</source>
<volume>89</volume>: <fpage>333</fpage>&#x02013;<lpage>337</lpage>.<pub-id pub-id-type="pmid">12865926</pub-id></mixed-citation></ref><ref id="pone.0108562-Shen1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Shen</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Hu</surname></name> (<year>2004</year>) <article-title>Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population</article-title>. <source>Cancer Lett</source>
<volume>206</volume>: <fpage>51</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">15019159</pub-id></mixed-citation></ref><ref id="pone.0108562-Jacobsen2"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Jacobsen</surname><given-names>NR</given-names></name>, <name><surname>Nexo</surname><given-names>B</given-names></name>, <name><surname>Olsen</surname></name> (<year>2003</year>) <article-title>No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer</article-title>. <source>Cancer Epidemio Biomar Preven</source>
<volume>12</volume>: <fpage>584</fpage>&#x02013;<lpage>585</lpage>.</mixed-citation></ref><ref id="pone.0108562-Fontana1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Fontana</surname><given-names>L</given-names></name>, <name><surname>Bosviel</surname><given-names>R</given-names></name>, <name><surname>Delort</surname><given-names>L</given-names></name> (<year>2008</year>) <article-title>DNA repair gene <italic>ERCC2, XPC, XRCC1, XRCC3</italic> polymorphisms and associations with bladder cancer risk in a french cohort</article-title>. <source>Anticancer Res</source>
<volume>28</volume>: <fpage>1853</fpage>&#x02013;<lpage>1856</lpage>.<pub-id pub-id-type="pmid">18630471</pub-id></mixed-citation></ref><ref id="pone.0108562-Shen2"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Shen</surname><given-names>M</given-names></name>, <name><surname>Hung</surname><given-names>RJ</given-names></name>, <name><surname>Brennan</surname><given-names>P</given-names></name> (<year>2003</year>) <article-title>Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case control study in northern Italy</article-title>. <source>Cancer Epidemiol Biomarkers Pre</source>
<volume>1</volume>: <fpage>1234</fpage>&#x02013;<lpage>1240</lpage>.</mixed-citation></ref><ref id="pone.0108562-Hosseini1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Hosseini</surname><given-names>M</given-names></name>, <name><surname>Houshmand</surname><given-names>M</given-names></name>, <name><surname>Ebrahimi</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>RAD51 polymorphisms and breast cancer risk</article-title>. <source>Mol Biol Rep</source>
<volume>40</volume>: <fpage>665</fpage>&#x02013;<lpage>668</lpage>.<pub-id pub-id-type="pmid">23065228</pub-id></mixed-citation></ref><ref id="pone.0108562-Wang1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>WW</given-names></name>, <name><surname>Spurdle</surname><given-names>AB</given-names></name>, <name><surname>Kolachana</surname><given-names>P</given-names></name> (<year>2001</year>) <article-title>A single nucleotide polymorphism in the 5_ untranslated region of <italic>RAD51</italic> and risk of cancer among <italic>BRCA1/2</italic> mutation carriers</article-title>. <source>Cancer Epidemiol Biomark Prevent</source>
<volume>10</volume>: <fpage>955</fpage>&#x02013;<lpage>960</lpage>.</mixed-citation></ref><ref id="pone.0108562-Krupa1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Krupa</surname><given-names>R</given-names></name>, <name><surname>Sliwinski</surname><given-names>T</given-names></name>, <name><surname>Jarosinska</surname><given-names>M</given-names></name> (<year>2011</year>) <article-title>Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer &#x02013; a case control study</article-title>. <source>Mol Biol Rep</source>
<volume>38</volume>: <fpage>2849</fpage>&#x02013;<lpage>2854</lpage>.<pub-id pub-id-type="pmid">21104022</pub-id></mixed-citation></ref><ref id="pone.0108562-Jarosiska1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Jarosi&#x00144;ska</surname><given-names>MW</given-names></name>, <name><surname>Sliwi&#x00144;fski</surname><given-names>T</given-names></name>, <name><surname>Krupa</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>The role of RAD 51 gene polymorphism in patients with colorectal cancer in the Polish subpopulation</article-title>. <source>Pol Merkur Lekarski</source>
<volume>26</volume>: <fpage>455</fpage>&#x02013;<lpage>457</lpage>.<pub-id pub-id-type="pmid">19606696</pub-id></mixed-citation></ref><ref id="pone.0108562-Makowska1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Makowska</surname><given-names>HR</given-names></name>, <name><surname>Samulak</surname><given-names>D</given-names></name>, <name><surname>Michalska</surname><given-names>M</given-names></name> (<year>2012</year>) <article-title>
<italic>RAD51</italic> gene polymorphisms and sporadic colorectal cancer risk in poland</article-title>. <source>Pol J Pathol</source>
<volume>3</volume>: <fpage>193</fpage>&#x02013;<lpage>198</lpage>.</mixed-citation></ref><ref id="pone.0108562-Sant1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Sant</surname><given-names>L</given-names></name>, <name><surname>Sucheston</surname><given-names>LE</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name> (<year>2011</year>) <article-title>Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk</article-title>. <source>BMC Cancer</source>
<volume>11</volume>: <fpage>1471</fpage>&#x02013;<lpage>1477</lpage>.</mixed-citation></ref></ref-list></back></article>